Taken together, these findings further highlight the predictive value of PTEN status in prostate cancer and emphasize the need for future work to identify beneficial stratification strategies for PTEN-deficient prostate cancer in order to better inform clinical trial design and improve patient care. This evidence concerns the gene PTEN and prostate carcinoma.